Switch theme
Sign up to access all valuation multiples
BioRegenx Inc develops and manufactures medical test equipment and high-quality, science-based nutritional products. The Company distributes wellness devices. The products are sold nationally through a direct selling channel to health professionals and research organizations. The company operates and manages its business as one reportable and operating segment as a medical testing, diagnostic and nutraceutical company. The Company focuses on commercialization of its patented technologies in its field.
1998
10
Last FY Revenue $2.3M
Last FY EBITDA -$20.5M
$12.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, BioRegenx achieved revenue of $2.3M and an EBITDA of -$20.5M.
BioRegenx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioRegenx valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $2.3M | XXX | XXX | XXX |
| Gross Profit | XXX | $1.7M | XXX | XXX | XXX |
| Gross Margin | XXX | 71% | XXX | XXX | XXX |
| EBITDA | XXX | -$20.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -878% | XXX | XXX | XXX |
| EBIT | XXX | -$6.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | -280% | XXX | XXX | XXX |
| Net Profit | XXX | -$23.1M | XXX | XXX | XXX |
| Net Margin | XXX | -985% | XXX | XXX | XXX |
| Net Debt | XXX | $2.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, BioRegenx's stock price is $0.
BioRegenx has current market cap of $10.8M, and EV of $12.8M.
See BioRegenx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.8M | $10.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, BioRegenx has market cap of $10.8M and EV of $12.8M.
BioRegenx's trades at 5.5x EV/Revenue multiple, and -0.6x EV/EBITDA.
Equity research analysts estimate BioRegenx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioRegenx's P/E ratio is not available.
See valuation multiples for BioRegenx and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.8M | XXX | $10.8M | XXX | XXX | XXX |
| EV (current) | $12.8M | XXX | $12.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -2.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -25.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioRegenx's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.8M for the same period.
BioRegenx's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioRegenx's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioRegenx and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -878% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 351% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Beamtree | XXX | XXX | XXX | XXX | XXX | XXX |
| Cogstate | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| Impedimed | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioRegenx acquired XXX companies to date.
Last acquisition by BioRegenx was XXXXXXXX, XXXXX XXXXX XXXXXX . BioRegenx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BioRegenx founded? | BioRegenx was founded in 1998. |
| Where is BioRegenx headquartered? | BioRegenx is headquartered in United States of America. |
| How many employees does BioRegenx have? | As of today, BioRegenx has 10 employees. |
| Is BioRegenx publicy listed? | Yes, BioRegenx is a public company listed on PINX. |
| What is the stock symbol of BioRegenx? | BioRegenx trades under BRGX ticker. |
| Who are competitors of BioRegenx? | Similar companies to BioRegenx include e.g. Beamtree, Cogstate, Echo IQ, Impedimed. |
| What is the current market cap of BioRegenx? | BioRegenx's current market cap is $10.8M |
| Is BioRegenx profitable? | Yes, BioRegenx is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
